A5074492256- Inflammatory Bowel Disease
- Microscopic Colitis
- Immune Cell Function and Interaction
- IL-33, ST2, and ILC Pathways
- Cancer Immunotherapy and Biomarkers
- Adolescent and Pediatric Healthcare
- Pregnancy and Medication Impact
- Mobile Health and mHealth Applications
- Clinical Nutrition and Gastroenterology
- Psoriasis: Treatment and Pathogenesis
- Acute Lymphoblastic Leukemia research
- Extracellular vesicles in disease
- Inflammasome and immune disorders
- Dialysis and Renal Disease Management
- Biomarkers in Disease Mechanisms
- Cytokine Signaling Pathways and Interactions
- Pregnancy and preeclampsia studies
- Gut microbiota and health
- T-cell and B-cell Immunology
- Central Venous Catheters and Hemodialysis
- Immunodeficiency and Autoimmune Disorders
- Systemic Lupus Erythematosus Research
- Pharmaceutical studies and practices
- Dermatology and Skin Diseases
- Renal Diseases and Glomerulopathies
Rijnstate Hospital
2017-2023
Radboud University Nijmegen
2016-2018
Radboud University Medical Center
2016-2018
A dysregulated intestinal T cell response is presumed in patients with inflammatory bowel disease [IBD]. In this longitudinal study, we investigated the changes lymphocyte subsets IBD at first presentation and over time during endoscopic active or inactive disease, relate them to activity outcome.We included 129 newly diagnosed (87 Crohn's [CD], 42 ulcerative colitis [UC]) 19 healthy controls [HC]. Follow-up biopsy specimens were analysed from 70 patients. Immunophenotyping of was performed...
The integrin CD103 is proposed to be a potential therapeutical target in inflammatory bowel disease (IBD), as it can form heterodimeric with β7 (Etrolizumab, anti-β7 integrin) on epithelial T cells. Therefore, we aimed study the frequencies of different intestinal CD103+T-cell subsets, both CD4+ and CD8+, newly diagnosed, untreated IBD patients at baseline during follow-up, compared healthy controls.Intestinal biopsies from inflamed segments colonoscopy peripheral blood samples were...
It is important to assess which patients with psoriasis are more likely achieve high clinical responses on biologics. To the number of treatment episodes (TEs) that a 100% improvement in Psoriasis Area and Severity Index (PASI 100), PASI 90 or ≤ 5 at week 24 biological treatment, baseline patient characteristics predict response. Data from treated adalimumab, etanercept, infliximab ustekinumab were extracted prospective cohort. TEs described. Uni‐ multivariate regression analyses performed...
Immunotherapy, targeting programmed death-1 (PD-1) enhances antitumor T-cell activity in patients with malignancies. Blocking PD-1 or its ligand may lead to fulminant colitis as serious adverse event these patients. Since little is known of the presence and role PD-1+T cells different etiologies, we determined mucosal specimens inflammatory bowel disease, infectious (InfC), immunotherapy-related (ImC) healthy controls (HC).Newly diagnosed ulcerative (UC, n = 73), Crohn's disease (CD, 50),...
Background & AimsTissue-resident memory T (Trm) cells, both of the CD4 and CD8 lineage, have been implicated in disease flares inflammatory bowel disease. However, data are conflicting regarding profile human CD8+ Trm with studies suggesting proinflammatory regulatory functions. It is crucial to understand functional these cells context (new) therapeutic strategies targeting (trafficking of) gut cells.MethodsHere, we performed imaging mass cytometry, flow RNA-sequencing compare lamina...
PNAd and MAdCAM-1 addressins on venules are of importance in T-cell homing potential therapeutic targets ulcerative colitis (UC). Normally, PNAd+ high endothelial (HEVs) only present lymphoid organs, whereas small numbers MAdCAM-1+ can be seen non-lymphoid tissue. We aimed to study their presence the intestinal mucosa UC patients at diagnosis during follow-up, correlation with disease activity. Colonic biopsy specimens 378 were analyzed by immunohistochemistry for CD3, CD20, ERG, MECA-79...
Therapeutic strategies for patients with ulcerative colitis (UC) are based on patient- and disease-related factors in combination drug characteristics but fail to predict success individual patients. A considerable proportion of UC do not respond the biological vedolizumab. Therefore, pretreatment biomarkers therapeutic efficacy urgently needed. Mucosal markers related integrin-dependent T lymphocyte homing could be potent predictors.
The effect of the Dutch nationwide adjustment reducing 6-thioguanine nucleotide (6-TGN) target values (from 600-1200 to 320-630 pmol/8 × 108 red blood cells [RBC]) on toxicity and clinical outcome thiopurine treatment in patients with inflammatory bowel disease has not yet been established. Therefore, authors determined incidence toxicity-induced discontinuations efficacy at both concentrations.This retrospective study was performed treated azathioprine or mercaptopurine. Two groups were...
Monitoring of IBD patients on intravenous biologic treatment is recommended but time-consuming for and nurses. We developed a mobile application (app) to promote self-management studied its feasibility in clinical practice.Adult treated with infliximab or vedolizumab used the app over four treatments. The includes information modules an interactive timeline notifications blood tests health checks before treatment.In total, 55 participated whom 71% had Crohn's disease 85% infliximab....
The mucosal immune system is implicated in the etiology and progression of inflammatory bowel diseases. lamina propria epithelium gut mucosa constitute two separate compartments, containing distinct T-cell populations. Human CD4 programming regulation T cells, especially during inflammation, remain incompletely understood. We performed flow cytometry, bulk, single-cell RNA-sequencing to profile ileal intraepithelial cells (CD4CD8αα, regulatory (Tregs), CD69- CD69high Trm cells) controls...
BackgroundTertiary lymphoid organs (TLOs) comprising peripheral node addressin positive (PNAd+) and/or MAdCAM+ high endothelial venules (HEVs) have been found to play an important role in local immunological dysregulation chronic immune-mediated disorders and malignancies. Their presence a predictive value for disease course response therapy. Identification of these HEVs the early phase ulcerative colitis (UC) might help stratify patients enable personalised medicine. We aimed investigate at...
Abstract Objective The mucosal immune system is implicated in the etiology and progression of inflammatory bowel diseases. lamina propria epithelium gut mucosa constitute two separate compartments, containing distinct T cell populations. Human CD4 programming regulation cells, especially during inflammation, remains incompletely understood. Design We performed imaging mass cytometry, flow bulk single-cell RNA-sequencing to profile ileal intraepithelial cells (CD4CD8αα, regulatory (Tregs),...
Recently, a pro-inflammatory role has been suggested for CD103+ CD4+, but not the CD8+ mucosal T-cell subset in inflammatory bowel disease (Lamb et al 2016). As CD103 integrin is target of new therapies with anti-β7 monoclonal antibodies, it important to analyse numbers different lymphocyte subsets active and remission. Here, we aimed study frequencies newly diagnosed, untreated IBD patients at baseline during follow-up, compared healthy controls (HC). Newly diagnosed Crohn’s (n = 75; CD),...
Abstract Background With the approval of tofacitinib, an oral Janus Kinase (JAK) inhibitor, modulation kinase activity has been added to therapeutic armamentarium inflammatory bowel disease (IBD). Despite its established efficacy, at least a third patients will not respond this or other options such as anti-tumour necrosis factor (TNF), anti-interleukin (IL)23/IL12 compounds vedolizumab. A better understanding profile could aid in tailoring drugs individual patients. We therefore explored...
Abstract Background Immunotherapy-related colitis is a frequent adverse event in patients with malignancies, treated inhibitors targeting programmed death-1 (PD-1). This treatment leads to enhancement of lymphocyte activity, thereby generating antitumor T-cell activity. The role PD-1+ T cells the pathophysiology different types unclear. Therefore, we aimed study presence inflammatory bowel disease (IBD), infectious and healthy controls compared anti-PD-1-related colitis. Methods We performed...
Abstract Background Active monitoring of IBD patients during intravenous (iv) biologic treatment is recommended but time-consuming and inconvenient for both nurses. We developed a mobile application to promote self-management monitor cost-effectively iv treatment. aimed study the feasibility application. Methods A prospective cohort was performed in secondary care centre with adult treated infliximab or vedolizumab at least three months. The used four rounds (figure 1). includes information...
Aim: The effect of the Dutch nationwide adjustment reduced 6-TGN target values (from 600-1200 pmol/8x108 RBC to 320-630 RBC) on toxicity and clinical outcome thiopurine treatment in patients with inflammatory bowel disease (IBD) has not yet been established. Therefore authors determined incidence toxicity-induced discontinuations efficacy at both concentrations. Methods: This retrospective study was performed IBD treated azathioprine or mercaptopurine. Two groups were defined: former (FT)...